Aiolos Bio

About:

Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.

Top Investors: RA Capital Management, Sofinnova Investments, Atlas Venture, Bain Capital Life Sciences, Forbion Capital Partners

Description:

Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by an accomplished team with decades of drug development experience and leadership in the biotech industry.

Total Funding Amount:

$245M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2023-01-01

Founders:

Khurem Farooq

Number of Employees:

11-50

Last Funding Date:

2023-10-24

IPO Status:

Private

Industries: